Insight

ctDNA-based MRD and survival in resectable colorectal cancer

grmedcenter.com

Nov 18, 2024, 01:05

ctDNA-based MRD and survival in resectable colorectal cancer

A recent paper by Yoshiaki Nakamura et al. was mentioned by Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, on X:

“ctDNA-based molecular residual disease and survival in resectable colorectal cancer”

Authors: Yoshiaki Nakamura et al.

“ctDNA-based MRD and survival in resectable CRC.

CIRCULATE- GALAXY, 2,240 patients.
shorter DFS in MRD+ patients.
Better outcome after sustained ctDNA clearance in response to ACT.
What else do we need to implement into clinical practice?”

Ibrahim Halil Sahin, Assistant Professor at UPMC Hillman Cancer Center, shared this post, adding:

“Nice data!

To answer what else needed to implement into daily practice? Interventional trials

This is only an observational study and we don’t change our practice based on observations! There is still significant false negative results we observe! One time testing may not be enough to de-escalate…

I encourage everyone to enroll in ongoing interventional trials such as CIRCULATE-NA or DYNAMIC III.”

More posts featuring Arndt Vogel and Ibrahim Halil Sahin.

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer.

He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.